Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
USP2 antisense RNA 1 (USP2-AS1)
- Target
- USP2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
USP2 antisense RNA 1 (USP2-AS1) is a long non-coding RNA (lncRNA) with strong pro-oncogenic functions demonstrated in multiple cancer types, including head and neck squamous cell carcinoma, hepatocellular carcinoma, ovarian cancer, colon cancer, and lung cancer[1][4][6][7]. USP2-AS1 is transcriptionally regulated by oncogenic factors such as HIF1α (under hypoxic conditions) and c-Myc[1][3][4]. It promotes cancer cell proliferation, cell cycle progression, invasion, and inhibits cellular senescence, mainly by interacting with regulatory proteins such as DCAF13, G3BP1, and YBX1, leading to alterations in the stability and translation of key mRNAs involved in tumorigenesis (e.g., E2F1, HIF1α)[1][3][4]. High levels of USP2-AS1 are associated with poor prognosis in several cancers and it is being investigated as a biomarker for cancer prognosis and as a potential therapeutic target, though there are currently no known direct drug interactors or approved drugs targeting this lncRNA[1][4][6][7].
- Other names
- THY1-AS1gLINCglycoLINCUSP2 antisense RNA 1 (head to head)
02
Biological functions
Regulation of gene expression (transcriptionally and post-transcriptionally)Cell proliferationCell cycle progressionInhibition of cellular senescenceCancer cell invasion and migrationRegulation of protein stability (via interactions with DCAF13, YBX1)
03
Disease associations
Cancer (pro-oncogenic activity in head and neck squamous cell carcinoma, hepatocellular carcinoma, ovarian cancer, colon cancer, lung cancer)
04
Biomarkers
Potential prognostic biomarker for cancer progression (e.g., head and neck squamous cell carcinoma, hepatocellular carcinoma)
Beyond the preview
Go deeper on USP2 antisense RNA 1 (USP2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USP2 antisense RNA 1 (USP2-AS1).